A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer
- To determine the maximum tolerated dose (MTD) of EPO906 administered in combination
with radiation therapy and establish a recommend phase II dose.
- To evaluate the safety and toxicity profile of EPO906 when administered concurrently
with radiotherapy in three disease cohorts.
- To evaluate tumor response.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) of EPO906 when administered to the following patient cohorts who receive 3-7 weeks of radiotherapy
Adam Dicker, MD, PhD
Thomas Jefferson University
United States: Food and Drug Administration
|Thomas Jefferson University Hospital||Philadelphia, Pennsylvania 19131|